Humana Raises 2025 Profit Forecast to $17 EPS, Shares Jump 5% on Medical Cost Stabilization

Humana Inc. (NYSE: HUM) nudged up its profit forecast for 2025, citing a stabilization in medical costs that have been a thorn in the side of the Medicare Advantage market for the past couple of years. The health insurer's shares edged up nearly 5% in early trading following the announcement, reflecting some renewed confidence among market watchers.

Humana, a heavyweight in the Medicare Advantage arena, benefits from a government-backed model where they receive fixed payments to manage healthcare for seniors and disabled individuals. The sector has struggled through the last two years with rising medical expenses driven by increased use of services across these government-sponsored plans.

But the latest quarterly update suggests Humana has managed to keep its medical cost ratio-a key metric showing the portion of premiums funneled into medical claims-mostly in check. It came in at 89.7%, slightly higher than last year's 88.9%, but right on the money compared to analyst expectations calling for 89.7%. This means the company's spending on medical care remains relatively stable despite ongoing industry headwinds.

One factor behind the stronger-than-expected numbers was better membership trends in Humana's individual Medicare Advantage plans, combined with growth in its primary care arm, CenterWell. The company also dialed back its anticipated decline in Medicare Advantage membership, signaling some resilience in its customer base.

CEO Jim Rechtin sounded optimistic, noting the company's "solid performance" during the first half of the year and maintaining confidence in insurance pricing as a lever for margin improvements.

On the earnings front, Humana posted a quarterly profit of $6.27 per share, comfortably beating the analyst consensus of $5.92. This helped the insurer raise its full-year profit projection to roughly $17 per share, up from the earlier estimate of $16.25 and comfortably ahead of the $16.38 average forecast.

Not bad at all for a business wrestling with the unpredictable forces of medical inflation and shifting patient behaviors. Whether Humana can keep this streak going remains to be seen, but for now, the numbers suggest it's navigating the challenges better than many expected.